» Articles » PMID: 7398740

Disposition and Pharmacodynamics of Diuretics and Antihypertensive Agents in Renal Disease

Overview
Specialty Pharmacology
Date 1980 Jul 1
PMID 7398740
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacodynamic actions and disposition of diuretic and antihypertensive agents may be significantly modified in subjects with renal disease. Most studies on this question have dealt with alterations in the elimination kinetics of these drugs and, while they generate descriptive data, minimal insight about changes in dose-response relationships or mechanisms of drug action are provided by such investigations. Several basic principles which may serve as useful guidelines in determining how renal failure will influence the response to drugs have been considered. They include the following: degree of renal malfunction, intrinsic toxicity of the drug, alternative pathways for drug metabolism and elimination, elimination pharmacokinetics and dose-response characteristics. Several classes of diuretic agents (thiazides, furosemide) and antihypertensive drugs (hydralazine, methylopda, propranolol, prazosin, and clonidine) have been used as models to define how basic knowledge of renal and non-renal pathways for elimination of drugs and their pharmacodynamic actions may assist in establishing rational therapeutic regimens for these agents in patients with renal failure.

Citing Articles

Pharmacokinetics of furosemide in neonates.

VERT P, Broquaire M, Legagneur M, Morselli P Eur J Clin Pharmacol. 1982; 22(1):39-45.

PMID: 7094973 DOI: 10.1007/BF00606423.


Pharmacokinetics of hydrochlorothiazide in relation to renal function.

Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schafer-Korting M, Mutschler E Eur J Clin Pharmacol. 1983; 24(5):661-5.

PMID: 6873147 DOI: 10.1007/BF00542218.


Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency.

DODION L, Willems J Eur J Clin Pharmacol. 1986; 31 Suppl:49-51.

PMID: 3780839 DOI: 10.1007/BF00541467.

References
1.
Waldmeier P, Hedwal P, Maitre L . On the role of alpha-methyldopamine in the antihypertensive effect of alpha-methyldopa. Naunyn Schmiedebergs Arch Pharmacol. 1975; 289(3):303-14. DOI: 10.1007/BF00499983. View

2.
Carr K, Rane A, Frolich J . A simplified assay of furosemide in plasma and urine by high-pressure liquid chromatography. J Chromatogr. 1978; 145(3):421-7. DOI: 10.1016/s0378-4347(00)81371-7. View

3.
McLeod P, OGILVIE R, Ruedy J . Effects of large and small doses of hydrochlorothiazide in hypertensive patients. Clin Pharmacol Ther. 1970; 11(5):733-9. DOI: 10.1002/cpt1970115733. View

4.
DAY M, Rand M . A hypothesis for the mode of action of alpha-methyldopa in relieving hypertension. J Pharm Pharmacol. 1963; 15:221-4. DOI: 10.1111/j.2042-7158.1963.tb12778.x. View

5.
Heise A, KRONEBERG G . Central nervous alpha-adrenergic receptors and the mode of action of alpha-methyldopa. Naunyn Schmiedebergs Arch Pharmacol. 1973; 279(3):285-300. DOI: 10.1007/BF00500607. View